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In this paper, we describe the emergence and evolution of pharmaceutical research at the German 
company E. Merck during the late 19
th and early 20
th century. Revolutionary changes in the sci-
entific knowledge base, especially the rise of bacteriological research, and the market entry of 
dyestuff producers into pharmaceuticals made the re-organisation of pharmaceutical research 
during the 1890s a necessary corporate strategy. Consequently, Merck restructured its in-house 
research between 1895 and 1898. Moreover, the firm deepened its co-operation with universities 
and other outside inventors. Jointly and severally, the firm depended on outside inventors for the 
generation of new products, whereas in-house scientists improved the productive efficiency. 
Moreover, we show that a significant number of new products were launched between the late 
1890s and 1905. During the following years, however, resource constraints restricted Merck’s 
innovative capacity.  
JEL-Classification: N 83, O 32 
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I.   Introduction  
Germany’s rise to one of the leading industrial economies during the late 19
th and early 20
th cen-
tury was, among many other reasons, ascribed to its ability to innovate. In particular, Germany’s 
success during the ‘second’ industrial revolution was connected to the inventions made in the 
fields of chemistry, pharmacy, and electrical engineering. In turn, the inventive activity was fos-
tered by the high quality of Germany’s system of higher education, the substantial governmental 
support for science, and – last but not least – the emergence of industrial research laboratories 
(Landes, 1999: 290-291; Cameron / Neal, 2003: 242-243).  
More specifically, the invention of the company-sponsored research organisation was identified 
as the undoubtedly greatest single contribution of the German dyestuff industry (Beer, 1959: 73). 
This path-breaking organisational revolution transformed the firms from fellow-runners to mar-
ket leaders in synthetic dye production. At least since Beer’s observation, the research laborato-
ries of the dyestuff industry itself had been the object of scientific research. The focus of these 
studies had been the development at Bayer (e.g., Beer, 1959; Meyer-Thurow, 1982; Murmann, 
2006) whereas the two other major dyestuff producers, BASF and Hoechst, were much less in-
tensively investigated (Homburg, 1992; Reinhardt 1997).
1  
Yet, the evidence of a science-based second industrial revolution is much less clear for other in-
dustries. König (1995, 1996) showed that the causality between industrial development and sci-
entific research was opposite in electrical engineering, compared to the experience of the dye-
stuff industry. Electrical engineering was an industry-driven science, not a science-driven indus-
try. In addition, Erker (1990) pointed out that professionally managed centralized research labo-
ratories emerged during the 1920s, and not during the pre-World War I period. Before World 
War I, research was decentralized at the major German electrical engineering firms Siemens and 
AEG. Moreover, centralized research laboratories appeared at about the same time in the U.S., 
Germany, and other European states.  
Turning to the pharmaceutical industry, findings by Wimmer (1994) show that professionally 
managed in-house research and development (R&D) was constricted to Bayer, whereas Hoechst 
procured new products from universities and only improved the production process in-house.
2 
Furthermore, the traditional pharmaceutical company Schering failed to develop a R&D strategy 
during the pre-World War I period (Wimmer, 1994; Kobrak, 2002). Jointly and severally, it 
seemed that the professionally managed centralized corporate R&D laboratory was constricted to 
dyestuff production. Moreover, all but one dyestuff firm – Bayer – failed to transfer the R&D 
organisation to the new field of pharmaceuticals.
3 
A detailed case study from the pharmaceutical industry is potentially important for this debate in 
several respects. First of all, most studies regarding the emergence of corporate R&D focus on 
                                        
1  Reinhardt (1998) contains a short English summary of the main findings of his monograph.  
2  Wimmer (1998) contains a short English summary of the main findings of his monograph.  
3  Nevertheless, Liebenau (1984, 1985) showed that German firms were market leaders in pharmaceutical   
research compared to their American and British competitors. 3 
the dyestuff industry. This industry clearly deserves a substantial amount of attention, since in-
dustrial R&D laboratories were invented in this industry. On the other hand, dyestuffs were rela-
tively unimportant in terms of output. In 1913, they accounted for only 3.5 percent of the value 
of the worldwide chemical production, whereas pharmaceuticals accounted for 17.5 percent 
(Ungewitter, 1931: 6). Second, the pharmaceutical knowledge base experienced a major shift 
during the 1870s and 1880s. More specifically, the sources of bacteriological infections were 
discovered and treatments for them were developed. Moreover, it turned out that dyestuff-
derivatives could be used as antipyretics and analgesics. Consequently, traditional pharmaceuti-
cal firms, whose knowledge based mainly on alkaloid chemistry, were faced with a new knowl-
edge base and with the market entry of the major dyestuff producers into the drug market.
4 Faced 
with this shift in general conditions, the major dyestuff and pharmaceutical firms adapted their 
behaviour.
5  
This paper offers a detailed case study about the emergence, organisation, and development of 
R&D at E. Merck, the oldest pharmaceutical company in the World.
6 So far, only the expansion 
of the research laboratories of the German dyestuff producers Hoechst, Bayer, and BASF to-
wards pharmaceutical research as well as R&D at the traditional pharmaceutical firm Schering 
had been evaluated (Wimmer, 1994; Reinhardt, 1995; Kobrak, 2002). These case studies showed 
a substantial heterogeneity in the organisation of R&D: Bayer developed strong in-house re-
search capacities, Hoechst mostly relied on long-term research co-operations with university re-
searchers, Schering depended upon the creativity of an individual in-house researcher, and BASF 
left the pharmaceutical market quite soon.  
Merck is an important case study for at least three reasons. First, Merck is a much older firm 
than Hoechst, Bayer, BASF, and Schering, which were all established during the 1860s, whereas 
Merck dates back to the late 17
th century and was established as a general partnership in 1827. 
Consequently, its learning base and organisational structure were built up during a different state 
of scientific knowledge. Second, Merck was a family-owned and managed firm whereas the 
large competitors were publicly quoted joint-stock companies, often with outside managers. 
Third, Merck was a major player in pharmaceutical research. Taking the number of innovative 
pharmaceutical products on sale in 1911/ 12 as a measure, Merck was number four on the Ger-
man market (Wimmer, 1994: 228).  
By and large, our case study shows a success story. We present evidence that Merck was not 
captured by its traditional knowledge base or its family-based management. Jointly and sever-
ally, Merck’s R&D strategy was similar to Hoechst’s strategy. Merck mostly relied on external 
                                        
4   Moreover, the role of small pharmacies and the distribution of drugs changed significantly after the introduc-
tion of industrial production (Wimmer, 1991).  
5   This shift in the knowledge base is comparable to the shift induced by the bio-tech revolution of the 1970s. 
Galambos / Sturchio (1998) evaluate the bio-tech revolution from the perspective of business history. Domin-
guez-Lacasa (2006) evaluates the consequences of established knowledge bases at German pharmaceutical 
companies for the adaptation to the new technology since the 1970s.   
6   Huhle-Kreutzer (1989: 121-150) described the innovative activity of Merck from the 1830s until the 1950s 
from a medical-historical perspective.  4 
researchers for the development of new products. Nevertheless, the firm had substantial in-house 
research capacities, which were radically re-organized in 1898 with the establishment of its cen-
tral research laboratory. The main activity of this laboratory was the screening of dozens of in-
ventions offered by outside inventors and the improvement of production processes. However, 
Merck’s success strongly depended on a small number of blockbuster drugs. In this respect, the 
firm was similar to its main competitors. Moreover, Merck failed to devote substantial resources 
to in-house R&D. Consequently, when the supply of product innovations from outside innova-
tors flattened during the last years preceding the Great War, Merck’s innovativeness declined 
substantially. 
The remaining parts of the paper are organized as follows. In Section II, an aggregate picture of 
R&D at Merck between the 1890s and World War I is depicted. Section III describes Merck’s 
external sources of innovation, e.g., cooperation with universities and the buying of production 
innovations on the market for technology. Section IV presents the in-house R&D capacities of 
the firm. The final Section V concludes the paper.  
II.   The development of E. Merck  
Merck’s history can be traced back to 1688, when Friedrich August Merck bought the Engel-
Apotheke (‘Angel pharmacy’) in Darmstadt, a small city south of Frankfurt. The move to indus-
trial production was initiated in 1827 by Emanuel Merck, who founded, together with his sons 
Carl, Georg, and Wilhelm, the business partnership E. Merck. From the 1880s onwards, the third 
generation of the Merck family controlled the business. All family members were well trained to 
manage the company: Carl’s oldest and youngest sons, Johann Heinrich Emanuel Merck and 
Carl Merck, received both a management education and were responsible for the commercial 
affairs of the company until 1897/ 98, when this activity was taken over by the chemists Louis 
Merck, the third brother, until his death in 1913. Georg’s sons, Emanuel August Merck and 
Willy Merck, were responsible for the sales department (1883-1923) and the production depart-
ment (1886-1932), respectively. Both had received a PhD in chemistry and pharmacy before en-
tering the firm. Willy’s sons, Carl Emanuel Merck, a chemist, and Georg Merck – who had a 
degree in management – managed the social affairs department (1888-1909) and the U.S. sub-
sidiary (1891-1926), respectively (Bernschneider-Reiff, 2002: 64-65).
7 
Beyond changes in the top management of the firm, the invention of bacteriological drugs and 
the use of dyestuffs as pharmaceuticals were two major changes of the scientific basis of phar-
maceutical research, which both occurred during the 1880s. This made a fundamental restructur-
ing of R&D indispensable. Moreover, changes in the scientific basis caused the market entry of 
                                        
7   American readers should note that Merck & Co., Whitehouse Station, U.S., was founded in 1891 as the U.S. 
subsidiary of the German firm E. Merck. After the confiscation during World War I, Merck & Co. became an 
independent company. Today, the firms are not linked together, but share the same name. Merck & Co. has 
the right to use the name in the U.S., but outside the U.S. it is known as Merck Sharpe & Dohme (MSD). 
Merck KGaA, in turn, has the right to use the name outside the U.S. and operates in the U.S. as EMD (for E. 
Merck, Darmstadt). The early history of MSD is analyzed by Galabmos / Sewell (1995).    5 
the large chemical firms Hoechst, Bayer, and BASF into the market for pharmaceuticals. Conse-
quently, the competitive and technological pressure on Merck increased substantially during the 
1880s and 1890s.    
The path-breaking bacteriological and immunological research conducted by Louis Pasteur and 
Robert Koch since the 1870s resulted into the discovery of the tubercle bacillus in 1882 and the 
cholera bacillus one year later.
8 In a very short period thereafter, almost all infectious diseases 
had been identified and pharmaceutical research related to these findings started soon. In a first 
step, vaccines against bacteriological infections were invented, followed by the development of 
sero-therapy. This latter type of medical treatment was brought forward by Emil von Behring 
and Paul Ehrlich.
9 In 1894, they developed the first drug in this line of research, an antidiphtheric 
serum. In 1910, Paul Ehrlich invented the first antibiotic, Salvarasan, which was the first drug to 
cure syphilis and a blockbuster for Hoechst, one of Merck’s main competitors.  
The usefulness of dyestuffs as pharmaceuticals was discovered during the 1880s. The first major 
drug in this regard, the antipyretic Kairin, was originally developed in search of a new dyestuff, but 
launched as a drug in 1883 by Hoechst (Wimmer, 1994: 150-151). The other German dyestuff 
firms followed soon with similar drugs: BASF introduced Thallin in 1885, Kalle & Co. launched 
Antifebrin in 1886, and Bayer rolled Phenacetin out in 1888 (Reinhardt, 1995: 253-254).
10  
Merck was not the first mover using the new pharmaceutical knowledge base. For instance, the 
three Nobel-Prize winning researchers Koch, von Behring, and Ehrlich signed research contracts 
with the dyestuff and pharmaceutical company Hoechst in 1892 and 1894, respectively. More-
over, Hoechst, as well as Bayer, deepened their in-house pharmaceutical research capacities. In 
turn, this increased the pressure on traditional pharmaceutical companies to collaborate with uni-
versity researchers and to establish own research units. Consequently, the Berlin-based company 
Schering established a bacteriological department in 1893 and hired a scientist for general phar-
maceutical and chemical research at about the same time. Merck followed soon and opened its 
bacteriological unit in 1895 (Bernschneider-Reiff, 2002: 55-57). In addition, Merck deepened its 
research co-operations with university researchers by establishing relationships with I. Stilling 
(in 1890), Rudolf Kobert (in 1892), Martin Freund (in 1895), Hugo Winternitz (in 1897), Josef 
von Mering (in 1898), Richard Wolffenstein (in 1900), and Richard Willstätter
11 (in 1900). Fur-
thermore, the internal organization of R&D at Merck was re-organized in 1898 with the estab-
lishment of the central scientific laboratory.
12  
                                        
8   Robert Koch received the Nobel Prize for medicine in 1905, Louis Pasteur died in 1895, before the endow-
ment of the Nobel Foundation.  
9   Emil von Behring was the first winner of the Nobel Prize for Medicine. Paul Ehrlich received the Nobel Prize 
for Medicine in 1908.  
10   These changes in the medical knowledge base made it more and more difficult for individual pharmacists to 
produce all known drugs by themselves. Thus, the production of pure basic chemicals as well as of ready-to-
use prescription and over-the-counter (OTC) drug shifted to industrial firms. Merck, for example, distributed 
such ready-to-use prescription and OTC drugs as ‘specialities’ (Patent- und Specialpräparate) to pharmacies, 
doctors, and consumers (Bernschneider-Reif, 2002: 53-54). 
11   In 1915, Richard Willstätter received the Nobel Prize for Chemistry.  
12   MRO, F3 / 2c.  6 
The major shifts in the scientific and organisational environment of the 1880s and 1890s are also 
numerically visible, in input as well as in output figures. Global input factors for a firm are the 
number of employees and the value of capital in use. More specifically for R&D are the number 
of employees and the money spent on these activities. The total number of Merck’s employees 
increased continuously from 714 in 1895 to 1,135 in 1901, and finally to 2,082 in 1914.
13 The 
number of scientists employed in the central research laboratory was, on the other hand, roughly 
constant at about eight researchers between 1898 and World War I. Yet, the total number of re-
searchers employed by the firm was larger, since some researchers were located in other depart-
ments of the company, for example in the bacteriological laboratory, the scientific information 
department, the control laboratory, and in several production units.
14 
A more comprehensive picture of resources devoted to R&D can be gained by locking at the 
amount of money spent. The in-house research budget was, compared to modern standards, 
moderate.
15 The average research budget spent during the three business years 1902/ 03 to 1904/ 
05 was 93,197 Mark, about 7 percent of profits or 0.8 percent of turnover.
16 In addition, Merck 
spend on average 16,923 Mark on its R&D cooperation with university researchers.
17 More spe-
cifically, this money was used to buy licences from professors and to equip their laboratories 
with staff and material. Moreover, various outside inventors – who were mainly university pro-
fessors – received on average about 80,000 Mark per year as remuneration for their inventions 
used by Merck.




A widely-used, albeit incomplete, measure of innovative output is the number of patents 
granted.
20 For Germany, this indicator is available from 1877 onwards, since the first unified 
German patent law was enacted during this year. Yet, the grant of pharmaceutical and chemical 
patents became much easier after the 1891 patent law reform act and the number of patents 
granted to these industries increased substantially thereafter.
21 Compared to the U.S. and U.K. 
                                        
13   MRO F3/2a, MRO F3/5a, and MRO F3/18a. Thus, Merck was much smaller than the big chemical compa-
nies BASF, Bayer, and Hoechst, but larger than Schering (1,227 employees in 1913), Chemische Fabrik von 
der Heyden (1,509 employees), and J.D. Riedel (1,001 employees), see Ungewitter (1931).    
14   In 1912-14, the number of scientists in the central research laboratories of BASF, Bayer, and Hoechst was 
29, 15, and 28, respectively (Reinhardt, 1997: 286, 365-366; Marsch, 2000: 66).    
15   In 2006, Merck invested about 12 percent of its turnover into R&D.  
16   During 1902-04, the average annual research budget of the pharmaceutical firm C.F. Boehringer & Söhne 
(Mannheim) was 110,233 Mark and that of Knoll & Co. (Ludwigshafen) was 36,514 Mark. In terms of assets 
and profitability, both firms were much smaller than Merck. Boehringer was about half the size of Merck, 
whereas Knoll was only about one-sixth of Merck’s size. MRO H5/43. 
17   MRO H5/43. 
18   Own calculations from Merck’s internal annual reports, MRO F3/7a, MRO F3/8a, and MRO F3/9a. 
19   Detailed figures about the research budget are not available for later years. However, the number of research-
ers in the central laboratory was more or less constant until World War I. Therefore, the expenditures for in-
house research can be expected to remain constant. Expenditures for external research, on the other hand, in-
creased substantially. In 1912, for example, Merck spent about 300,000 Mark to compensate outside inven-
tors. 
20   Grilliches (1990) reviews the usefulness of patents as an indicator for innovations. More specific for the 
German historical context are Grupp et al. (2002) and Metz / Watteler (2002).  
21   See Seckelmann (2005) for a detailed account of the history of Germany’s patent law. On aggregate, the 
number of patents granted in 1893-95 was 14 percent higher than the number of patents granted in 1890-92. 7 
patent systems, four features of the German patent law were outstanding. First, a patent was 
granted to the person registering the patent at the patent office and not to the true inventor. Con-
sequently, inventions made by employed inventors were granted to the firms employing them.
22 
Moreover, long-term research contracts between firms and university researchers often allocated 
the patent to the firm.
23 Second, a detailed technical examination of the invention was made by 
the patent office. In addition, patent infringements were mostly settled in the period between the 
publication of a patent application and the grant of the patent. Therefore, patents granted repre-
sented secure property rights.
24 Third, it was compulsory to put the patent into use within three 
years after it was granted. Consequently, individual inventors or university professors had a 
strong incentive to sell or licence their patents to firms. Fourth, patenting of pharmaceutical final 
products was forbidden by patent law; only the production process could be patented. Moreover, 
even patenting of processes was quite difficult until the 1891 patent law reform. Thus, imitation 
of final products of competitors using slightly modified processes was common practice.
25 In 
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Figure 1 
Annual patenting activity by Merck 
Source: Kaiserliches Patentamt, Verzeichnis der erteilten und in Kraft befindlichen Patente, various years. 
                                                                                                                           
Patents for the chemical and pharmaceutical industries (technology classes 12 and 22) increased, on the other 
hand, by about 87 percent.   
22   More than 60 percent of all patents were granted to firms.  
23   See Section III for the case of Merck.  
24   Less than 0.4 percent of the patents granted were repealed after the grant.  
25   Lee (2003) showed that coexistence of innovation and imitation within one firm was common in the U.S. 
pharmaceutical industry until the 1940s, whereas thereafter firms were either innovators or imitators.  8 
Merck received its first patent on 6 October 1885 (patent-no. 35,724) for a method to manufac-
ture peptone using nucleon proteins (Löw, 1952: 47).
26 Until the reform of the patent law in 
1891, Merck’s patenting activity was nearly non-existent (see Figure 1). From 1892 onwards, on 
the other hand, eight patents were on average granted to Merck annually. In addition, Merck 
bought 28 patents from other inventors and sold three patents on the market for intellectual prop-
erty rights. As could be expected, nearly all of Merck’s patents (151 out of 174) were granted in 


























































Number of patents in force Patent fees paid
 
Figure 2 
Merck’s patent stock and its cost 
Source: Kaiserliches Patentamt, Verzeichnis der erteilten und in Kraft befindlichen Patente, various years. 
 
The annual flow of new patents granted to Merck or acquired by Merck resulted into a growing 
stock of patents held by the company. In turn, the costs of keeping the patents active increased 
substantially during the early 20
th century (see Figure 2).
28 Merck’s patent stock surpassed ten in 
1894 and 100 in 1905. The fees paid surpassed 5,000 Mark in 1899 and 10,000 Mark in 1906. 
The patent stock of the company peaked in 1907/ 08 with 117 patents in force (1907) and 14,590 
Mark fees paid (1908) respectively. Thereafter, the patent stock and the fees paid declined sub-
stantially to 74 patents in force and 3,430 Mark fees paid in 1913. The patent data thus show a 
                                        
26   Peptones are used as a culture medium in bacteriological research.  
27   The Imperial Patent Office allocated the patent classification according to the industry of use, not according 
to the industry of origin. 
28   Keeping a patent in force was expensive in the German Empire. The owner of a patent had to pay an annual 
fee, which increased from 30 Mark for the first year to 50 Mark for the second year, 100 Mark for the third 
year, 150 Mark for the fourth year, and so on. The fee for the 15th and final year was 700 Mark. Thus, the 
cumulated fee for 15 years of protection was 5,280 Mark, about 6.5 times the annual per capita income in 
1913. 9 
marked increase in innovative activity at Merck during the first years of the 20
th century, fol-
lowed by a crisis of innovation during the years preceding the Great War.  
R&D resources were converted into patentable innovations, and these innovations should have 
been used in final products sold by Merck. Therefore, resources devoted to R&D and patenting 
activity should be visible in output figures for R&D intensive products. In general, Merck dou-
bled its turnover from 5.7 million Mark during the business year 1894/ 95 to 11.5 million Mark 
in 1902/ 03 and then again to 23 million Mark in 1912.
29 The turnover of Merck’s specialities 
(i.e., prescription and OTC drugs) increased, on the other hand, by factor four between the turn 
of the century and World War I.
30 Furthermore, prescription and OTC drugs were very profit-
able. In 1902/ 03, Merck’s total profit was 1.36 million Mark, about 11.8 percent of the annual 
turnover.
31 In 1912, total profits were roughly 3.9 million Mark, about 17 percent of the turn-
over. In 1902/ 03, about 13.1 percent of the total profits were generated by the specialities. Ten 
years later, in 1912, about 28.5 percent of the profits were made with these R&D intensive prod-
ucts.
32 This illustrates the rising importance of R&D intensive products for Merck.  
As today, pharmaceutical companies generated most of the profits with a small number of block-
buster products. Table 1 shows Merck’s blockbuster products. The table is derived from the 
product-specific accounts, which Merck kept for its most important products. The product-
specific accounts include information about turnover, marketing expenditure, profits, and remu-
neration of outside inventors. In 1897/ 98, eleven products were separately accounted for, in 








                                        
29   In 1913, Bayer generated a turnover of about 22 million Mark with pharmaceuticals (Wimmer, 1994: 143). 
Hoechst’s turnover with pharmaceuticals was about 4.8 million Mark in 1909 and 6.4 million Mark in 1910 
(Wimmer, 1994: 185). Schering generated a total turnover of about 16.8 million Mark in 1913 (Ungewitter, 
1931: 55-62). Consequently, Merck was much smaller than Bayer, but of Hoechst’s size in the field of phar-
maceuticals. Schering, on the other hand, was smaller than Merck.   
30   MRO, F3/1b, MRO, F3/7c, MRO F3/16d. Until 1906, Merck’s business year ran from 1 July to 30 June. It 
was changed to the calendar year from 1907 onwards.  
31   MRO H5/43. 
32   MRO F3/16d. Schering’s turnover (net profit) was 8,947 Million Mark (465 million Mark) in 1895 and 
16,840 Million Mark (1,416 million Mark) in 1913 (Kobrak, 2002: 360-361). Therefore, Merck had a faster 
growth of turnover and a higher profitability than Schering.   
33   MRO F3/1b and MRO F3/16a. Moreover, separate accounts are available for the 27 products covered by a 
pharmaceutical cartel agreement. Burkert (1990) described the history of this cartel agreement.   10 
TABLE 1: CUMULATED NET PROFIT OF MERCK'S TOP PRODUCTS 
  
From product launch 
until 1913 
From product launch 
until 1918 
   in Mark  Rank  in Mark  Rank 
Stypticin  1,190,520.70 1  1,603,771.47 1 
Dionin  967,335.69 2  1,290,547.51  4 
Jodipin  646,946.08 3  763,577.11 5 
Perhydrol  571,993.02 4  1,325,977.57  3 
Tannoform  388,272.03 5  733,313.91 6 
Veronal  356,348.31 6  1,490,926.51  2 
Haemol  245,372.95 7  261,828.56 10 
Magnesium-Perhydrol  218,218.18 8  491,174.53 8 
Pyoktanin  142,383.81 9  401,653.26 9 
Fibrolysin  114,844.23 10  195,535.43 11 
Total  4,842,235.00     8,558,305.86    
MRO, S 6-21 and S 6-22. 
 
Merck’s most important product was the haemostasis drug Stypticin, which generated a profit of 
nearly 1.2 million Mark between its launch in 1897 and the end of 1913. Dionin, a morphine de-
rivative antitussive drug, generated profits of nearly one million Mark between its rollout in 1898 
and 1913. Jodipin and Haemol were both bacteriological drugs used in fighting streptococcus, 
tubercle, and syphilis. Perhydrol and Magnesium perhydrol were disinfectants applied in den-
tistry and – in a lower concentration – as a mouthwash. Veronal, which was jointly developed 
and sold with Bayer, was the first barbiturate. Pyoktanin, which based on dyestuffs, was used to 
treat mycosis of the eye. Fibrolysin and Tannoform, finally, were used to sanitise wounds, the 
latter also in treatment of intestinal diseases.
34      
Similar product-specific accounts were also kept at Bayer and Hoechst (Wimmer, 1994: 120-
122, 185-187). In 1897, for example, Bayer generated a turnover of 4.66 million Mark and a 
profit of 1.36 million Mark with its most important pharmaceuticals (Wimmer, 1994: 120). This 
compares to a turnover of only 0.43 million Mark and profits of about 67,000 Mark at Merck 
during the business year 1897/ 98. Consequently, Merck’s drug business was much smaller and 
less profitable during the late 1890s than Bayer’s. In addition, few blockbuster products were 
responsible for the major part of turnover and profits at all companies. In 1909, for example, 
Hoechst generated about half of its pharmaceutical turnover with its two top-selling drugs, Anti-
pyrin and Pyramidon (Wimmer, 1994: 185-186). In a similar fashion, Merck generated 40 per-
cent of its pharmaceutical turnover with its two blockbuster drugs Veronal and Dionin in 1909.
35    
                                        
34   It is important to note that Merck made substantial profits producing more traditional products. For example, 
Merck’s cocaine production generated a turnover of more than 1.5 million Mark and a profit of more than 
400,000 Mark in 1912.   
35   In 1913, Schering generated drug sales of 2.7 Million Mark, about 15.9 percent of the total sales of the com-
pany. The two most important drugs, Atophan and Urotropin, accounted for nearly three-quarters of Scher-
ing’s pharmaceutical sales (Kobrak, 2002: 364).  11 
The above mentioned data regarding the money spend for R&D already suggested that a substan-
tial part of the R&D expenditures was used to compensate outside inventors. Actually, Merck’s 
top ten drugs of the pre-World War I era were all invented by outside inventors (see Table 2). In 
this respect, Merck was very similar to Hoechst: 21 out of 24 of Hoechst’s high-value pharma-
ceuticals developed between 1883 and 1909 were invented by outsiders (Wimmer, 1994: 185).  
TABLE 2: SOURCES OF MERCK'S TOP PRODUCTS 
  




Share in profits 
for inventor (on 
profits until 
1918) 
Stypticin Martin  Freund University  1897 31.2% 
Dionin  Joseph von Mering University  1898  27.0% 
Jodipin Hugo  Winternitz  University  1902  20.3% 
Perhydrol  Richard Wolffen-
stein  University 1900  8.6% 
Tannoform  Joseph von Mering University  1895  5.1% 
Veronal  Emil Fischer / Jo-
seph von Mering  University 1903  36.8% 
Haemol R.  Kobert  University  1892  50.0% 
Magnesium-Perhydrol  Richard Wolffen-
stein  University 1903  8.1% 
Pyoktanin I.  Stilling  University  1890  25.2% 
Fibrolysin  Dr. F. Mendel  free inventor  1905  22.6% 
MRO, F 3 (diverse files); MRO R 15 / 11; MRO R 15 / 12.  
 
Merck’s top product Stypticin was invented by Martin Freund, a professor of medicine in Frank-
furt. Moreover, Freund invented the less successful, but still profitable, drugs Methyl-
Narcotamid and Hydrastinin. The most important outside inventor for Merck was most likely 
Joseph von Mering, professor of medicine at the University of Halle. Mering, born 1849 in Co-
logne, studied medicine in Bonn, Strasbourg, and Greifswald. He earned his PhD in Strasbourg 
in 1874 and worked in clinics in Strasbourg and Halle. Finally, he was appointed to a full profes-
sorship and directorship of the University clinic in Halle in 1900. He was the inventor of two of 
Merck’s top-selling drugs (Dionin and Tannoform) and the co-inventor of Veronal. Moreover, he 
invented two of the less profitable drugs sold by Merck.
36  
                                        
36   The drug Peronial earned a profit of 26,014 Mark until 1913. Hydrogen peroxide earned a profit of 21,447 
Mark. Other university professors co-operating with Merck were the Nobel Prize winner Emil Fischer, inven-
tor of Proponal and co-inventor of Veronal; Hugo Winternitz, inventor of Jodipin, Bromipin, Chineonal, and 
Luminal; and Richard Wolffenstein, inventor of Perhydrol, Magnesium-Perhydrol, and Zinc-Perhydrol.   12 
III.   Research collaboration and the market for technology  
Until today, the collaboration of industrial firms and universities is an important component of 
pharmaceutical research (Chandler, 2005). During the two decades preceding World War I, the 
emergence of such co-operation was fostered by Germany’s patent law, which prescribed the 
application of a patent within three years after it was granted. Otherwise, the patent was repealed 
and the knowledge was available for free. Consequently, university professors and other outside 
inventors, who did not possess the necessary means to produce drugs on a large scale, were 
forced to sell or licence their patent. University professors as well as firms realized this problem 
in advance and often closed long-term research contracts, which allocated the right of use of a 
patent to the firm and a substantial remuneration to the inventor.  
For example, Merck’s most successful drug, Stypticin, was developed by Martin Freund, a pro-
fessor of medicine in Frankfurt, during the 1890s. This drug was based on water soluble crystals 
being vasoconstrictive and was used as haemostasis drug.  The business relationship between 
Merck and Freund began in February 1891, when they signed a long-term research contract. The 
stipulations agreed upon in this contract are typical for other contracts closed by Merck. The 
contract ran for at least five years, but was prolonged automatically thereafter if both parties did 
not terminate the agreement with a period of notice of 15 months. Merck paid a fixed amount of 
2,000 Mark annually to Freund, who had to spend this money to hire a research assistant and to 
cover the running expenses of his research laboratory. In turn, all product or process innovations 
discovered had to be presented to Merck before publication in a scientific journal. All innova-
tions became the joint property of Merck and Freund and the firm decided on the commercial 
exploitation of the invention. If the innovation seemed to become a commercial success, Merck 
had to produce and distribute it on an industrial scale. Freund, on the other hand, had to support 
the diffusion of knowledge about the innovation in the scientific community, to fill the patent in 
Merck’s name, and to defend the patent against infringements of third parties. In addition, all 
profits were shared between Merck and Freund. For each product, the exact profit share of the 
two parties depended on the degree of patent protection. In general, Freund’s share varied be-
tween 15 and 50 percent of the accounting profit.
37 In the case of the blockbuster Stypticin, for 
example, Freund’s profit share was 30 percent of the net profit, indicating that the patent was not 
water-proof.
38 
One result of the product-specific profit sharing was that Merck kept product specific accounts 
for up to 80 products during the pre-World War I period. These accounts contain information 
about revenues, production costs, and marketing costs. More specifically, the production costs 
included the running expenses for chemicals, heating material, wages, etc., as well as informa-
tion about depreciation (capital costs) for the capital stock used for the production of a single 
drug. The accounting method was standardized, and most of Merck’s outside inventors had the 
                                        
37   A very similar contract was closed in March 1901 with Richard Willstätter. Willstätter received a fixed com-
pensation of 6,000 Mark annually, the relevant material free of charge, and a profit share of 25 percent. MRO 
R15/12. 
38   MRO R5/23.  13 
right to inspect the accounts. By and large, the accounts were undisputed during the pre-1913 
era. Only one conflict regarding the accounts is documented for the pre-World War I period. 
From 1903 onwards, Merck sold the blockbuster barbiturate Veronal, which was invented by 
Joseph von Mering and Emil Fischer. Several years after the successful launch of the drug, Emil 
Fischer pointed to the fact that the depreciation on the capital stock used for the production of 
Veronal was too high and therefore his profit share too low. During a meeting, Merck informed 
Fischer that Merck’s usual depreciation rate on buildings was five percent per annum. Fischer, 
however, pointed out that a depreciation rate of two percent would be sufficient. Without any 
discussion, Merck agreed to this request, adapted the accounts, and used the new depreciation 
rate for this product from 1907 onwards.
39 
Controversies regarding the assessment base for the compensation of outside inventors emerged 
more often. Generally, outside inventors could receive a fixed amount and / or a variable amount 
related to profits, revenues, or output. By and large, Merck – as well as other chemical and 
pharmaceutical companies – favoured a variable compensation, since then the risk was shared 
between the inventor and the firm, whereas a fixed compensation shifted the risk towards Merck. 
Most outside inventors agreed without debate to a variable compensation. Yet, whether the vari-
able compensation was based on profits, revenues, or output was disputed. For example, Martin 
Freund, the inventor of Stypticin, and Merck negotiated about the modus of Freund’s compensa-
tion for several months during 1906-07.
40 The starting point was Merck’s offer to switch from a 
profit-based compensation of 30 percent of the accounting profits to an output based compensa-
tion of 80 Mark per kg from May 1906.
41 Yet, Freund figured out that his average compensation 
since the launch of the drug equalled about 15 percent of the turnover, or about 85 Mark per kg. 
Merck justified its lower offer by continuously rising wages, increasing input costs, and growing 
costs for administration and marketing. In particular, Merck pointed to the tremendously rising 
costs for noscapine, the most important input factor for the production of Stypticin.
42 It soon 
turned out that Freund and Merck could not agree on a fixed compensation per kg. Thus, the 
profit-sharing agreement remained in force. In September 1907, the discussion came up again 
when Martin Freund visited Merck’s factory. At this opportunity, Freund pointed to the fact that 
the profit-turnover ratio of Stypticin had been declined recently. Freund offered two possible 
solutions: Merck could increase the price for Stypticin or could switch Freund’s compensation to 
a turnover- or output-based measure. Again, Merck pointed to the rising costs for noscapine and 
to a profit-sharing agreement closed with Knoll, the producer of the competing drug Stypta, 
which complicated the switch from a profit-based compensation to any other form of compensa-
                                        
39   Letter from Merck to Fischer, 7 February 1908, MRO H5/15. In this letter, Merck informed Fischer that the 
acquisition costs for the buildings and other fixed assets used for the production of Veronal were 97,500 
Mark and 142,280 Mark, respectively.  
40   This is documented in various letters of Freund, Merck, and the competing pharmaceutical firm Knoll. MRO 
F1/47. 
41   Merck and Freund agreed upon an output-based compensation for another product, hydrastinin hydrochlo-
ricum, in 1902. Contract between Merck and Freund, 1 July 1902, MRO R5/23. 
42   Letter from Merck to Freund, 20 December 1906. MRO F1/47. 14 
tion since then the contract closed with Knoll had to be adapted.
43 Consequently, the profit-
sharing agreement between Freund and Merck remained in force.
44 
One key responsibility of outside inventors was the protection of the patent against infringements 
by competitors. As a matter of course, a successful product like Stypticin encouraged competing 
firms to develop similar products. The success of the drug is clearly visible in output and profit 
figures: the amount sold rose from 11.2 kg in 1897 to 187.6 kg in 1902; productions costs de-
clined from 253 Mark to 142 Mark per kg during the same period; marketing costs decreased 
from 175 Mark to 53 Mark per kg. The price per kg, on the other hand, remained on a high level, 
decreasing only from 703 Mark in 1897 to 562 Mark in 1902. Consequently, profits per kg in-
creased substantially from 205 Mark in 1897 to 311 Mark in 1902.
45   
Already in 1896, Merck had expected that the Stypticin patent was vulnerable and fixed Freund’s 
share in profits at 30 percent, well below the maximum of 50 percent agreed upon in the Freund-
Merck research contract for a water-proof patent, but also much higher than the minimum share 
in profit of 15 percent. In January 1903, Merck’s patent was bypassed by the German pharma-
ceutical company Knoll & Co., which received a patent for a close substitute, Stypta. Martin 
Freund filed an objection against Knoll’s patent at the Imperial Patent Office and a long-lasting 
legal dispute was fought between Freund and Merck, on one side, and Knoll and Dr. Vieth – the 
inventor of Knoll’s product Stypta – on the other.  
After three years of conflict, Knoll approached Merck to close a market-sharing agreement for 
Stypticin and Stypta.
46 Knoll proposed a profit-sharing agreement allocating at least two-thirds 
of the joint profits of both firms to Merck. If the profits generated by Merck were higher than 
two-thirds of the joint profits, Merck would not transfer any profits to Knoll. This proposal indi-
cates that Knoll’s patent most likely infringed Merck’s patent. Moreover, Knoll asked Merck to 
close the agreement very soon since the Patent Office expected an elaboration of Knoll’s patent 
within two weeks. Soon, Merck regarded Knoll’s proposal with favour and agreed to withdraw 
its patent litigation after signing a profit-sharing agreement. The two firms negotiated the details 
of the market sharing agreement during the following two months and finally signed a contract, 
which was valid from 1 July 1906.
47 
Beyond the long-term research co-operation with university professors, Merck bought many in-
ventions from university professors as well as from free inventors.
48 This can be exemplified 
using the contracts closed with Dr. F. Mendel and Professor Hugo Winternitz, two inventors of 
                                        
43   Letter from Merck to Knoll, 12 September 1907. MRO F1/47. 
44   Finally, Merck and Freund switched from profit-sharing to another form of variable compensation in 1912. 
Yet, the details of these negotiations are not documented in the files.  
45   MRO F1/47. 
46   Letter Knoll to Merck, 30 April 1906, MRO F1/47. 
47   Knoll’s entry on the product market had consequences for prices, costs, and profits. Between January 1903 
and June 1906, the average price per kg was 573 Mark, production costs were 165 Mark, marketing costs 
were 71 Mark, and profits were 280 Mark. Compared to the period before Knoll’s market entry, the market 
price for the final product remained about constant. On the other hand, the production and marketing costs 
increased substantially. Consequently, profits per kg decreased by about ten percent compared to 1902. 
48   Dozens of contracts are contained in MRO R 15/12, MRO R 15/11, and MRO R1/42. 15 
Merck’s top products highlighted in Tables 1 and 2. Dr. Mendel was a medical practitioner in 
Essen and inventor of Fibrolysin, a drug used to sanitise wounds. According to the contract 
closed on 5 January 1905, Merck applied for a patent and trademark protection for the drug and 
produced, advertised, and distributed it on an industrial scale. Mendel, in turn, received 15 per-
cent of the accounting profits made during the validity of the patent.
49  
The second example concerns Hugo Winternitz, a professor for medicine, who was inventor of 
Bromipin (patented in 1897) and Jodipin (patented in 1902), two bacteriological drugs. On 29 
May 1900, Merck agreed to produce and distribute the two drugs. In case of Bromipin, Winter-
nitz licensed these rights to Merck, whereas in case of Jodipin, Merck bought (in 1904) the entire 
patent. In turn, Winternitz received a compensation of 7.50 Mark per kg of pure Bromipin and 
12-15 Mark per kg of pure Jodipin. These payments were, however, not fixed, but could be 
adapted to changing input or output prices. Moreover, the compensation was only payable as 
long as the patent was valid.
50 Consequently, Merck stopped payments to Winternitz for 
Bromipin in 1912 and for Jodipin in 1917. Moreover, the compensation for Jodipin was halved 
in 1912 to account for changing market conditions. Nevertheless, the output-based compensation 
scheme was indeed very lucrative for Winternitz. For Bromipin, he received 29,610 Mark until 
1912, about half of the total profits generated by this drug between 1897 and 1912. The Jodipin 
deal was less lucrative in relative terms for Winternitz, but more lucrative in absolute terms. Be-
tween 1902 and 1911 Winternitz received 140,730 Mark, about one-quarter of the profits gener-
ated by the product. Between 1912 and 1917, when the patent expired, he received another 
14,341 Mark, which equalled less than eight percent of the drug’s profits. Jointly and severally, 
the Bromipin-Jodipin deal was very profitable for both parties: until 1918, Winternitz earned 
nearly 185,000 Mark from his inventions and Merck got a profit share of about 650,000 Mark.
51 
Merck’s activity on the market for innovations went far beyond these acquisitions of blockbuster 
drugs. The company bought, among many others, inventions for the production of dental ce-
ment
52, the cost-efficient production of hydroquinone
53, the manufacture of the pneumococcus 
serum Jequiritol
54, the manufacture of anthrax sera
55, and the production of the cinnamic acid 
product Zebromal
56. A count of the product and process innovations highlighted in the annual 
reports of Merck’s scientific laboratory shows that 44 percent of all product innovations – not all 
innovations discussed in the reports were commercially or technically successful – had their ori-
gin in university laboratories, 28 percent were prepared by free inventors, and only 28 percent 
were made in-house. Altogether, close relationships with university researchers were the most 
                                        
49   MRO R 15/12. The product was very profitable until 1916 and generated smaller profits thereafter. Between 
1905 and 1918, Mendel received 44,024 Mark for his innovation from Merck. MRO S6/21 and MRO S6/22. 
50   Contract between Merck and Winternitz, 29 May 1900; MRO R 15/12. Letter Merck to Winternitz, 31 Octo-
ber 1911; MRO R 15/12. 
51   In 1912, Winternitz sold Chineonal to Merck. This drug was less successful than Bromipin and Jodipin and 
earned a cumulated loss of more than 25,000 Mark until 1918. MRO S 6/21 and MRO S 6/22. 
52   Contract between Merck and Carl Böttinger, 12 October 1898; MRO R 1/42.  
53   Contract between Merck and A. Lindemann, 23 April 1903; MRO R 1/42. 
54   Contract between Merck and P. Römer, 6 May 1905; MRO R 1/42. 
55   Contract between Merck and Georg Sobernheim, 10 December 1901; MRO R 1/42. 
56   Contract between Merck and A. Ellinger, 10 April 1912; MRO R 15/11. 16 
important source of product innovations for Merck, whereas the existing research capacity inside 
the firm was not sufficient to generate a continuous flow of new and commercially successful 
products.     
IV.   In-house R&D  
Merck’s in-house research capacities were rather unimportant for the generation of new prod-
ucts. Nevertheless, several important tasks were fulfilled by Merck’s researchers: they tested the 
product innovations offered by outside inventors, they scaled the production of new drugs and 
chemicals up from laboratory conditions to industrial production units, they tested the quality of 
inputs and of outputs, and they continuously improved the production processes. Challenging for 
the management was that Merck’s in-house R&D capacities were scattered over different de-
partments of the company. First of all, Willy Merck, co-owner of the firm and head of the pro-
duction department, was an active researcher. Moreover, subordinate managers in the production 
department, in particular Carl Scriba, were often trained chemists with an interest in process op-
timization. Furthermore, chemists and pharmacists were employed in the control laboratory, the 
scientific information department, the bacteriological department, and – last but not least –  the 
central research laboratory, which was established in 1898.
57 Furthermore, the research-related 
organisational units did not have well-defined areas of research, but intersected on many themes.   
The control laboratory tested the quality of inputs delivered to Merck and of the outputs to be 
shipped to customers. In addition, it traced the origin of customers’ complaints regarding product 
quality. During the business year 1897/ 98, for example, 9,638 preparations were evaluated in 
the control laboratory. At the time, two trained chemists, Dr. Braun and Dr. Neubert, between six 
and eight blue-collar workers, and one white collar worker were employed in the laboratory.
58 
Moreover, it was involved in process optimization, a task also fulfilled by the production units 
and the central scientific laboratory.  
The scientific information department, established in 1888, was mainly responsible for the in-
formation of the public about the latest innovations and of available products in pharmacy. The 
information was circulated using ‘Merck’s Jahresberichte’ (Merck’s digest), a booklet published 
in several languages and distributed all over the World.
59 The 1898 edition of Merck’s digest 
was, for example, published in four languages (German, English, French, and Russian) and dis-
tributed in 27,000 copies to customers and scientists worldwide. The production of this report 
was the main task of Dr. Paul Zipperer, head of the scientific information department. Moreover, 
Zipperer, a clerk and a part-time chemist, were responsible for responding to scientific questions 
arising from the departments of the company, from customers, and from outside scientists. In 
                                        
57   Therefore, Merck established a centralized research unit long before the foundation of its pharmaceutical 
research laboratory in 1927.  
58   MRO F3/2a. 
59   The following discussion is based on the review of activity of this department during the years 1888-1899, 
published in Merck’s internal report for the business year 1898/ 99. MRO F3/3a. 17 
1898, for example, 420 scientific correspondences with customers and outside researchers were 
handled and 2,175 enquiries from the various departments of the company were answered. Fur-
thermore, the department organized the scientific library as well as the circulation of 56 scientific 
journals inside the company. Finally, members of the scientific information department sup-
ported the other laboratories and tested 48 drugs and made 40 experiments. 
Bacteriological research was conducted at Merck since 1895 in the bacteriological production 
department headed by Dr. von Buisson. In addition, in August 1900 the bacteriological research 
laboratory headed by Dr. Landmann was established. Three years later, a new head of bacterio-
logical research was hired: Wilhelm Eicholz, who earned his PhD in chemistry in 1901 from 
Emil Fischer. Eichholz was one of the longest-serving researchers at Merck and he stayed at the 
firm until his death in 1927.
60 His most important contributions were his participation in the 
Jodipin research and his invention of a dysentery serum in 1906.
61 The main tasks of the bacte-
riological research laboratory were the quality control of the products of the bacteriological pro-
duction units as well as research regarding tubercle, typhus, and diphtheria. However, the re-
sources for research were rather limited. For example, resources devoted to the development of 
the first bacteriological drug, Tuberculol, were just 23,216.37 Mark, spent over a period of 
eleven years.
62 Furthermore, Dr. Landmann was part-time delegated to the bacteriological pro-
duction department. Moreover, the research unit was involved in quality control. For instance, 
105 samples of the production department were investigated in the bacteriological research labo-
ratory during 1900/ 01.
63 Nevertheless, in 1902, sera fighting tubercle, pneumococcus, and strep-
tococcus were launched, followed by a diagnostic drug for typhus one year later.
64 Later on, re-
search regarding diphtheria, typhus, and streptococcus was in the focus of the laboratory’s 
staff.
65 Parallel to the bacteriological research conducted in Darmstadt, a bacteriological research 
unit was established in co-operation with Professor Sobernheim in Halle. Merck installed a re-
search unit in Halle, directed by Sobernheim and staffed with Merck’s own researcher, Dr. Bu-
row. Burow started his research in May 1902 and worked for Merck until May 1911.
66 In par-
ticular, research in and production of an anthrax serum was conducted in Halle.   
The central scientific laboratory, headed by the chemist Dr. Alexander Ehrenberg, was founded 
in 1898 by combining the departments for synthetic analysis, the analytical laboratory, the elec-
tro-chemical laboratory, the patent office, and the marketing department.
67 Already one year 
later, the central research laboratory was re-organized by dividing it into four sub-units: (i) the 
                                        
60   MRO F3/1b. 
61   MRO J 10/715. 
62   MRO F3/5a. Merck made these expenditures between 18 March 1890 and 30 June 1901. Expenditures for a 
lymphe serum and another tubercle serum were 7,589.37 Mark (1 June 1896-30 June 1901) and 3,468.55 
Mark (24 May 1897-30 June 1901; Tuberculinum Kochii), respectively. 
63   MRO F3/5c.  
64   MRO F3/7a and MRO F3/7a. From a commercial point of view, these drugs were unimportant. In 1912, the 
turnover generated by the five drugs was less than 75,000 Mark and they made a profit of about 9,000 Mark.  
65   MRO F3/12c. In 1908, the bacteriological laboratory employed 18 blue-collar workers and one researcher, 
Dr. Eichholz. 
66   MRO R 15/11. Contracts Merck with Burow, 25 April 1902 and 15 May 1911. 
67   MRO F3/2c. 18 
operations laboratory; (ii) the experimental laboratory; (iii) the electro-chemical department; (iv) 
the office for patents and marketing. This organisational structure remained in place at least until 
World War I.   
Dr. Holzinger, the first staff member of the operations laboratory, improved the blueprints for 
new products from a laboratory scale to an industrial scale. Moreover, many new products were 
first produced and sold by the operations laboratory. Production was handed over to the produc-
tion department when the process was fully developed. The experimental laboratory, staffed first 
by Dr. Kassner and Dr. Schnerr, had three main tasks. First, it checked inventions offered to 
Merck by outside inventors regarding the applicability on an industrial scale; second, it improved 
established production processes; third, it developed new products. The electro-chemical labora-
tory, staffed with Dr. Pip from 1898 onwards, participated in the research projects of the opera-
tions and experimental laboratory by applying electro analysis. The office for patents and mar-
keting, finally, was responsible for safeguarding Merck’s inventions, monitoring the patenting 
activities of competing firms, and circulating Merck’s research results among scientists, users, 
and customers. In this office, Dr. Mennel was responsible for patents and Dr. Rahn for market-
ing.
68 
The size of Merck’s central research laboratory remained quite similar over time: the average 
number of researchers was eight, with nearly no fluctuation in absolute numbers, but with sig-
nificant fluctuation of individual researchers. More specifically, two career paths were common 
in Merck’s central research laboratory. First, some researchers stayed in their positions for very 
long periods. Examples are Dr. Pip, head of the electro-chemical laboratory from 15 January 
1898 and Dr. Beckh, who started on 1 December 1899 as a researcher in the experimental labo-
ratory. Both stayed in research – at least – until World War I. Other examples are Dr. Knell and 
Dr. Wolfes, who joined the experimental laboratory to conduct research on the barbiturate Ve-
ronal on 1 April 1903 and 21 November 1904 respectively; both stayed at least until World War 
I. The second typical research path was the move from research into production. Examples are 
Dr. Gruschwitz and Dr. Weber, members of the experimental laboratory during 1903-07 and 
1904-07 respectively. Other examples are Dr. Immel and Dr. Seuffert, who were members of the 
experimental laboratory for two years (1901-03), and Dr. Müller, who was a researcher for just 
six months in 1909. 
Merck’s central research laboratory main task was the ‘D’ part of R&D, i.e., the optimization of 
production processes for large-scale production. This function can be quantified by counting the 
process innovations discussed in the annual reports of Merck’s scientific laboratory: 88 percent 
of all process innovations can be ascribed to in-house researchers, whereas only six percent each 
originated from university researchers and free inventors.  
The annual reports of the laboratory also include numerous case studies for process optimisation. 
For example, Albert Ladenburg, professor for chemistry in Breslau, demonstrated in 1894 the 
                                        
68   MRO F3/4a. 19 
electro-chemical reduction of pyridine to piperidine. One of the first tasks of Dr. Pip, head of the 
electro-chemical research unit, was the adaptation of Ladenburg’s method to an industrial scale. 
He succeeded soon and generated piperidine at a cost of 70 Mark per kg, 50 Mark per kg less 
than the original method. In addition, an optimized arrangement of the production process and 
the use of a modern filter press reduced the costs further to 50 Mark per kg. Merck’s researcher 
proposed to the management of the firm that the knowledge about the new substance should be 
circulated in universities. Then, some technical or medical use of piperidines was expected to be 
found soon.
69 Indeed, some time later, piperidine became an important intermediate in the syn-
thesis of drugs. 
Another example for process development relates to the research concerning the barbiturate Ve-
ronal, invented in 1903 by Fischer and von Mehring, who were outside researchers for Bayer and 
Merck, respectively. Consequently, this first barbiturate was produced by Bayer and Merck using 
very similar methods. Merck soon figured out that the theoretical derivation and small-scale 
laboratory production of this barbiturate were insufficient for industrial production. Conse-
quently, Merck hired two new researchers, Dr. Klein and Dr. Knell, to work exclusively on Ve-
ronal. The first major problem was the immense demand for the new drug, making large-scale 
production inevitable. Before the launch of the new drug, Merck estimated an annual demand of 
500 kg. Yet, the production capacity had to be expanded to 5,000 kg per annum within the first 
year and a further increase to 10,000 kg seemed possible if the production unit was used 24 hour 
a day.
70 During the following year, Veronal-related research capacities at Merck were increased 
further as Fischer’s former research assistant Dr. Wolfes was hired by the company. He was 
worth his money, since he substantially improved the use of alcohol in the production process. 
Thereby, he increased the rate of yield from 38 percent to 60 percent. Moreover, it seemed pos-
sible to increase the rate of yield to 70 percent. Nevertheless, Dr. Beckh, another researcher at 
Merck, reverse engineered the method used by Bayer and figured out that Bayer’s rate of yield 
was even higher. Nevertheless, Merck’s method was less expensive at the actual input prices.
71 
Naturally, Veronal’s high profitability – the profit-turnover ratio was 35 percent in 1903/ 04 – 
attracted market entrants. For example, Schering and Hoechst earned money on a Veronal-like 
drug using a method that had just one-third of the rate of yield of the Bayer-Merck method. Yet, 
Merck protected its product by applying for a series of patents around the original Veronal pat-
ent. In June 1905, just two years after the launch of Veronal, Merck already held 65 patents re-
garding Veronal – about two-thirds of Merck’s total patent stock was therefore related to this 
drug.
72  
                                        
69   MRO F3/2c. „Vor allem muß man jetzt versuchen, Universitäten und technische Hochschulen für das Piperi-
din zu interessieren, arbeiten größere wissenschaftliche Kreise mit diesem Stoffe, so wird sich auch bald eine 
Verwertung gefunden haben, sei es nun in medizinischer oder technischer Beziehung.“ 
70   MRO F3/7c. 
71   MRO F3/8c. 
72   MRO F3/9c. During 1905/ 06, the situation had stabilised and the prominence of Veronal in the research 
laboratory declined. Merck’s method was nearly as efficient as the one used by Bayer. In addition, Hoechst’s 
production was eliminated by a decision of the patent office. Schering’s production was interrupted by a de-
cision of the patent office. MRO F3/10c. 20 
The third example of process optimization concerns the production of tannins, an important raw 
material for the production of herbal pharmaceutics.
73 During the mid-1890s, Merck’s position in 
this market was endangered by a new process developed by Schering. To counter this attack, 
Merck experimented with five new processes for the production of tannins. The six input factors 
had to be composed in a way that the four different types of outputs were generated in a profit-
maximizing way at given market prices. In a first step, a new method was theoretically devel-
oped. This new method reached a rate of yield of 72 percent, much better than the 64 percent of 
Merck’s old method and above the rate of yield of Schering’s method. In a second step, the theo-
retical results had to be applied in practice. Between January and April 1897, Merck’s chemists 
tried five different modes of production. In practice, the new method had a rate of yield of 70.23 
percent, less than the model predicted for Merck’s method, but higher than the old process. As a 
result, the new process resulted in a decline of production costs from 2.60 Mark per kg to 2.20 
Mark per kg of tannin. The fact that the decline in production costs was relatively higher than the 
increase of the rate of yield is striking. This indicates that Merck’s researcher did not only im-
prove the process, but that they also optimized the structure of input factors in view of current 
prices. Moreover, the researchers expected declining costs due to learning effects of the workers 
and due to a new design of the manufacturing facility, which was expected to reduce the loss of 
ether, an input factor. Consequently, the chemists projected a decline of production costs to 2.10 
Mark per kg, nearly 20 percent less than the unit costs of the old process.
74 
In-house product development, on the other hand, mostly failed. A striking example is the pro-
duction of vanillin and heliotropine, two basic materials for perfume production. In 1874, the 
first chemical production of vanillin using the sap of spruce bark was realized by the German 
chemists Wilhelm Haarmann and Ferdinand Tiemann, who founded a firm – Haarmann’s Vanil-
lin-Fabrik – to exploit the patent. However, it took more than a decade and the invention of va-
nillin production using eugenol in 1891, to make the chemical production of it a big commercial 
success. A few years later, Merck decided to enter this market. During the business year 1897/ 
98, a new, four-step production method for vanillin was developed by Merck’s researchers. The 
first step was the relocation of eugenol to iso-eugenol using a new method, which was not in 
conflict with existing patents. However, the new method was not revolutionary enough to get a 
patent. In the second step, the iso-eugenol was acetylated and the resulting product was – in step 
three – oxidated to acetvanillin. Finally, vanillin was separated from acetvanillin. Moreover, 
economies of scope could be realized since the same instruments and machines used for the pro-
duction of vanillin could also be used in the production of heliotropine.
75 One year later, Merck 
received a patent for step two of its new method. Furthermore, large-scale experiments were 
conducted to get data for the estimation of future production costs and to optimise the production 
process. In addition, two investment plans were presented to the management of the firm. An 
entirely new facility for the production of vanillin and heliotropine would cost about 40,000 
                                        
73   The relevance of tannins for Merck can be shown using revenue and profit figures for 1908 and 1909. During 
these two years, tannins generated a turnover of more than 700,000 Mark (about 4 percent of total turnover) 
and profits of more than 110,000 Mark. MRO H5/9a.   
74   MRO F3/1a. 
75   MRO F3/2c. 21 
Mark, whereas the conversion of existing facilities would be possible at a cost of only 16,000 
Mark. The latter plan was agreed upon and the production on an industrial scale was bound to 
start during 1900.
76 However, it turned out that Merck’s method had a much lower rate of yield 
than expected from the laboratory experiments. Simultaneously, the market price of vanillin de-
clined substantially. Consequently, Merck was not able to compete on the product market. Nev-
ertheless, the management decided to continue the production since substantial fixed costs had 
already been sunk.
77 Yet, prices for vanillin and heliotropine declined further and the production 
was stopped in 1901, about one year after Merck’s entry into the market.
78   
At regular intervals, shortages of resources devoted to R&D were discussed in the annual reports 
of the central research laboratory. For example, resources were temporarily shifted from the cen-
tral research laboratory to the production units.
79 Another example of resource constraints con-
cerned the electro-chemical department. This department should have been equipped with many 
complex installations, but the necessary office and laboratory space was sometimes unavail-
able.
80 A final example concerns the experimental laboratory. Due to missing office space in the 
laboratory, no new scientists were hired in 1902 after the promotion of Dr. Immel and Dr. Seuf-
fert into the production department.
81 Even one of the core activities of the central research labo-
ratory, the protection of drugs using the patent system, was sometimes not completely fulfilled. 
The report for 1899/ 1900 states, for example, that the experiments to extend the patent protec-
tion of Merck’s cocaine processes were of only secondary importance for the researchers.
82 Fur-
thermore, the use of patent lawyers was restricted as far as possible to save money, and the cor-
responding tasks were performed in-house by Merck’s patent department.
83 Moreover, invest-
ment into laboratory equipment was sometimes delayed for several years, making some experi-
ments impossible.
84 
The remuneration of in-house researchers was very moderate, in particular if compared to the 
compensation of outside inventors. Merck’s standard working contract for chemists during the 
                                        
76   MRO F3/3c. Moreover, it turned out that the same method could be employed to produce paracetamol, a 
Aspirin-like drug.   
77   MRO F3/4c. 
78   MRO F3/5d. 
79   In 1908, Dr. Silberbach was delegated in the production department. During the following year, several re-
search chemists were delegated into the production department during the summer. During 1910 and 1911, a 
substantial part of the research manpower was delegated to the cocaine production. In 1913, research capac-
ity was shifted to the control laboratory since the researcher there was snowed under with work.     
80   MRO F3/3c for 1898/ 99, MRO F3/7c for 1902/ 03.  
81   MRO F3/6c. 
82   MRO F3/4c. Report of the head of the scientific laboratory, Dr. Ehrenberg, regarding cocaine research: „[…] 
Bei dieser Gelegenheit will ich indessen darauf aufmerksam machen, daß derartige Arbeiten im wissen-
schaftlichen Laboratorium durchaus nicht als Hauptsache angesehen werden, sondern daß sie zur Ausfüllung 
der bei den großen laufenden Hauptaufgaben übrig bleibenden Zeit dienen.“ 
83   MRO F3/4c. 
84   The 1908 report stated that the operations laboratory received, after several years of waiting, a large centrifu-
gal and a large agitating tub. The head of the scientific research laboratory, Dr. Beckh, claimed that this delay 
had negative consequence, for the scientific work as well as for the whole company: “Es kann nicht scharf 
genug auf den Schaden hingewiesen werden, welcher nicht nur der Wissenschaft, sondern auch der Fabrik 
durch ein derartiges Gebahren entsteht, und es ist zu hoffen, daß die jetzt vorhandenen Anfänge einer Ver-
suchsapparatur für Fabrikationszwecke dem Laboratorium dauernd erhalten bleiben.“  22 
early 20
th century prescribed that chemists were initially hired for one year, followed by an open-
ended contract with a period of notice of three months. The annual fixed income varied between 
2,400 Mark and 4,500 Mark. All inventions made were automatically transferred to Merck, and 
most contracts did not contain a profit-sharing agreement.
85 In this respect, Merck differed from 
Bayer, where the researchers received a share in product specific profits of up to five percent 
(Wimmer, 1994: 124-126; Meyer-Thurow, 1982: 373-375). Yet, in-house researchers at Bayer 
only received this profit share for new products and not for process improvements of external 
inventions. Therefore, Bayer’s in-house research staff impeded the acquisition of externally de-
veloped products (Wimmer, 1994: 140-141). In this respect, Bayer substantially differed from 
Merck and Hoechst.  
The intensity of the Veronal research and the resource constraints after 1908 were, in a way, re-
sponsible for the decline of in-house research at Merck. On the one hand, Veronal induced a rise 
of research capacities, since new scientists were hired. On the other hand, nearly all researchers 
were engaged in Veronal-related research between 1903 and 1906. As a result, the number of 
new patents declined tremendously after the end of the Veronal wave. Moreover, researchers 
were regularly delegated into the production department. Consequently, the research output de-
clined substantially. Jointly and severally, nearly no new research results were published in the 
reports of the central research laboratory after 1908. In 1909, Dr. Beckh summarised the situa-
tion for in-house research at Merck:
86  
“Although factory management has, over the years, not changed its mind as regards 
the many concerns facing the introduction of new drugs – concerns I myself share to 
a large degree –, nonetheless I cannot avoid being convinced that experiments aimed 
at obtaining new synthetic drugs should not be allowed to disappear altogether from 
the agenda of a scientific laboratory. This kind of work, particularly when it comes to 
inventing such superior quality products as Veronal, can be compared to a veritable 
hunt for the jackpot. And even if one contents oneself with a lesser level of success, 
if one goes only for the minor successes, this means a huge amount of futile work. 
                                        
85   MRO R 1/42. Contracts of Merck with: Dr. Erich Ruderson (1 June 1914; 3,600 Mark fix); Dipl. Ing. Ed-
mund Carl Burchard (1 July 1911, 4,500 Mark fix, unspecified profit share for inventions); Dr. A. Pister (10 
August 1914, 3,960 Mark fix); Dr. Ludwig Wolter (1 December 1914; 2,400 Mark fix).  
86   “Wenngleich sich die Anschauung der Fabrikleitung über die vielerlei Bedenken, welche der Einführung 
neuer Arzneimittel entgegenstehen, im Lauf der letzten Jahre nicht geändert hat, Bedenken welche ich selbst 
in hohen Maße teile, so kann ich mich doch der Überzeugung nicht verschließen, daß Versuche zur Gewin-
nung neuer synthetischer Arzneimittel nicht vollständig aus dem Arbeitsprogramm des wissenschaftlichen 
Laboratoriums ausgeschaltet werden dürfen. Die letztere Art von Arbeiten läßt sich, zumal wenn man Körper 
von so souveräner Qualität, wie das Veronal suchen will, wohl mit Jagen nach dem großen Loos vergleichen. 
Und selbst wenn man mit minderen Erfolgen zufrieden sein will, wenn man nur die kleineren Treffer sucht, 
steckt eine endlose Menge vergeblicher Arbeit darin. […] Durch Vervollkommnung unserer Betriebsmetho-
den werden wir unsere bisherigen großen Fabrikate wohl in der Mehrzahl der Fälle auf der Höhe halten kön-
nen und unsere Absatzgebiete behaupten, einen direkten FORTSCHRITT bedeutet dies aber nicht. Dabei 
müssen wir immer noch gegenwärtigen, daß die wirkliche chemische Großindustrie, die Farben- und Säure-
fabriken infolge der intensiv gesteigerten Konkurrenz sich allmählich unseren größeren Präparaten zu-
wenden, sie werden dann zweifellos in der Lage sein, selbst bei gleichwertigen Fabrikationsmethoden uns in-
folge der billigeren Rohstoffe in den betr. Artikeln zu unterbieten und so den Konsum an sich zu ziehen. Es 
sollte daher zur rechten Zeit Nachwuchs geschaffen werden, aber nicht durch aussichtslosen Kleinkram son-
dern durch einige gute Spezialitäten, dann durch Aufnahme einiger neuer Fabrikationszweige, die durch die 
Größe des Absatzgebietes und durch den Nutzen, mit dem sie nachweislich von anderer Seite vertrieben wer-
den, eine Garantie für dauerhafte Rentabilität bilden.“ MRO F3 / 13d. 23 
[…] By perfecting our operational methods we will most probably be able to main-
tain most of our major products on the same high standard, as well as holding our 
key markets; yet, this does not inevitably mean PROGRESS. We must still bear in 
mind that the real large-scale chemical industry, the dyestuff and acid factories, are 
gradually looking into producing the very same key substances we make, as a result 
of consistently growing competition. Using the same production methods as we do, 
they will no doubt soon be able to underbid us in these products, due to cheaper raw 
materials, thus attracting the consumer. For this reason, the ground should be pre-
pared for new innovations as soon as the time is right – not just some unpromising 
odds and ends, but a few good specialist products. Then, other new branches should 
be taken on board. This would provide a guarantee for sustainable cost-effectiveness 
as a result of an increased market area and demonstrable usefulness.”  
Moreover, Dr. Beckh asked for better co-operation between chemists and medical scientists, as 
well as for intensified co-operation with university researchers. In particular, the scientific in-
formation department should improve the flow of information from practioners and university 
researchers to the members of the central research laboratory. Only when these pre-conditions 
are met, the central research laboratory could focus on the most important research topics.
87 
V.   Conclusion 
During the 1880s and 1890s, traditional, alkaloid-based pharmaceutical research was challenged 
by the bacteriological revolution and by the discovery of dyestuff-based drugs. In addition, the 
latter development caused the market entry of dyestuff producers on the market for pharmaceuti-
cals. Consequently, product market competition intensified substantially at the turn of the 20
th 
century. Moreover, some dyestuff producers – especially Bayer – started systematic research to 
discover new drugs. Thereby, the traditional trial-and-error approach of alkaloid-based pharma-
ceutical research used by incumbent producers like Merck came under pressure. Furthermore, 
the foundation of the state-sponsored health insurance in Germany during the 1880s and the 
modification of the German patent law in 1891 increased the demand for drugs and enhanced the 
possibilities to appropriate profits from patent-protected products. Finally – and exceptionally for 
the family-owned firm Merck – a new generation of family members took over the management 
of the firm during the 1880s and 1890s. Jointly and severally, the period between 1890 and 1913 
was challenging for Merck.  
Merck responded to these multiple challenges by adapting its research strategy and organisation. 
First, a significant number of long-term research co-operations were initiated during the 1890s. 
In this regard, Merck’s strategy was similar to the one used by Hoechst, one of the large dyestuff 
producers entering the market for pharmaceuticals during the 1880s. Nearly all products 
launched by these firms were developed by university researchers, who were connected to the 
firms via long-term contracts. During the early 1890s, Bayer followed a similar strategy. Yet, at 
the turn of the century its in-house research capacities were sufficient to develop a continuous 
flow of new products. Schering, like Merck a traditional pharmaceutical company, was, on the 
                                        
87   MRO F3/13d.  24 
other hand, neither successful in establishing external research co-operations nor in setting-up in-
house research capacities.
88 
Second, Merck addressed the bacteriological revolution by setting-up a bacteriological produc-
tion unit in 1895. A bacteriological research laboratory was established in 1900. Finally, a close 
and long-lasting research co-operation with Professor Georg Sobernheim from the University of 
Halle began in 1902. In bacteriological research, Merck was not outpaced by its major competi-
tors. More specifically, Hoechst established in-house bacteriological research only in 1903, after 
the breakdown of the path-breaking research co-operation with Emil von Behring. Nevertheless, 
Hoechst kept its leading position in the market for bacteriological drugs. Bayer, on the other 
hand, did not focus on bacteriological research, and most of its drugs were based on salicylic 
acid derivatives. Schering, finally, established a bacteriological unit as early as 1893. However, 
the research activities of the firm mostly failed. By and large, Merck did not become a major 
player in bacteriological drugs. Nevertheless, the firm profitably produced the full range of those 
drugs during the pre-World War period. 
Third, Merck strengthened its in-house research capacities in 1898, the foundation year of its 
central research laboratory. Merck’s laboratory was, however, smaller than the research units of 
Bayer or Hoechst. In addition, the resources devoted by Merck to in-house research were often 
insufficient. Nevertheless, Merck successfully screened new products offered to the firm by out-
side inventors. Moreover, the firm established sufficient skills in chemical engineering to up-
grade the production processes of bought drugs from laboratory conditions to industrial scale. 
Merck’s in-house research strategy was therefore comparable to Hoechst’s. Yet, the flow of out-
side inventions flattened during the years preceding the Great War. On the other hand, resources 
devoted to in-house research were insufficient to compensate this development. In this respect, 
Merck’s development mirrors Hoechst’s experience during the same period. A possible strategic 
shift was perhaps delayed by the Great War: Hoechst founded its central pharmaceutical research 
laboratory in 1913, whereas Merck established its pharmaceutical research laboratory in 1927, 
after the Great War and the period of hyperinflation.    
  
 
                                        
88   The close co-operation between industry and university was also common in the U.S. Furman / MacGarvie 
(2007) have shown that close industry-university co-operation caused a flow of knowledge from universities 
to firms during the inter-war period.  25 
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